Autopsy report · NCT01131325
Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations
Cause of deathNo reason given
Life of this trial
- Registered 5 months before it started.
- Ran for about 7 months before it stopped.
- 3 participants enrolled.
- Results were posted on the registry 10 years after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- CML; Philadelphia Chromosome Positive (Ph+); Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels
- Interventions
- nilotinib
- Participants
- 3
- Sites
- 3
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.